Cargando…

Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas

SIMPLE SUMMARY: Diffusely infiltrating gliomas are frequent brain tumors with variable prognosis. In addition to the blood pigment’s role of oxygen transportation, the metabolic pathway synthesizing heme has been shown to play a role in the biochemistry of various tumors. In this study we thus inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Mischkulnig, Mario, Kiesel, Barbara, Lötsch, Daniela, Roetzer, Thomas, Borkovec, Martin, Wadiura, Lisa I., Roessler, Karl, Hervey-Jumper, Shawn, Penninger, Josef M., Berger, Mitchel S., Widhalm, Georg, Erhart, Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916021/
https://www.ncbi.nlm.nih.gov/pubmed/33562253
http://dx.doi.org/10.3390/cancers13040662
_version_ 1783657383575158784
author Mischkulnig, Mario
Kiesel, Barbara
Lötsch, Daniela
Roetzer, Thomas
Borkovec, Martin
Wadiura, Lisa I.
Roessler, Karl
Hervey-Jumper, Shawn
Penninger, Josef M.
Berger, Mitchel S.
Widhalm, Georg
Erhart, Friedrich
author_facet Mischkulnig, Mario
Kiesel, Barbara
Lötsch, Daniela
Roetzer, Thomas
Borkovec, Martin
Wadiura, Lisa I.
Roessler, Karl
Hervey-Jumper, Shawn
Penninger, Josef M.
Berger, Mitchel S.
Widhalm, Georg
Erhart, Friedrich
author_sort Mischkulnig, Mario
collection PubMed
description SIMPLE SUMMARY: Diffusely infiltrating gliomas are frequent brain tumors with variable prognosis. In addition to the blood pigment’s role of oxygen transportation, the metabolic pathway synthesizing heme has been shown to play a role in the biochemistry of various tumors. In this study we thus investigated the impact of heme biosynthesis factors mRNA expression on the survival in glioma patients and observed a progressive decrease in survival time with increasing mRNA expression signature. This association was present for overall as well as progression-free survival and remained statistically significant after correction for established prognostic factors such as patient age and tumor grade. ABSTRACT: Diffusely infiltrating gliomas are characterized by a variable clinical course, and thus novel prognostic biomarkers are needed. The heme biosynthesis cycle constitutes a fundamental metabolic pathway and might play a crucial role in glioma biology. The aim of this study was thus to investigate the role of the heme biosynthesis mRNA expression signature on prognosis in a large glioma patient cohort. Glioma patients with available sequencing data on heme biosynthesis expression were retrieved from The Cancer Genome Atlas (TCGA). In each patient, the heme biosynthesis mRNA expression signature was calculated and categorized into low, medium, and high expression subgroups. Differences in progression-free and overall survival between these subgroups were investigated including a multivariate analysis correcting for WHO grade, tumor subtype, and patient age and sex. In a total of 693 patients, progression-free and overall survival showed a strictly monotonical decrease with increasing mRNA expression signature subgroups. In detail, median overall survival was 134.2 months in the low, 79.9 months in the intermediate, and 16.5 months in the high mRNA expression signature subgroups, respectively. The impact of mRNA expression signature on progression-free and overall survival was independent of the other analyzed prognostic factors. Our data indicate that the heme biosynthesis mRNA expression signature might serve as an additional novel prognostic marker in patients with diffusely infiltrating gliomas to optimize postoperative management.
format Online
Article
Text
id pubmed-7916021
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79160212021-03-01 Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas Mischkulnig, Mario Kiesel, Barbara Lötsch, Daniela Roetzer, Thomas Borkovec, Martin Wadiura, Lisa I. Roessler, Karl Hervey-Jumper, Shawn Penninger, Josef M. Berger, Mitchel S. Widhalm, Georg Erhart, Friedrich Cancers (Basel) Article SIMPLE SUMMARY: Diffusely infiltrating gliomas are frequent brain tumors with variable prognosis. In addition to the blood pigment’s role of oxygen transportation, the metabolic pathway synthesizing heme has been shown to play a role in the biochemistry of various tumors. In this study we thus investigated the impact of heme biosynthesis factors mRNA expression on the survival in glioma patients and observed a progressive decrease in survival time with increasing mRNA expression signature. This association was present for overall as well as progression-free survival and remained statistically significant after correction for established prognostic factors such as patient age and tumor grade. ABSTRACT: Diffusely infiltrating gliomas are characterized by a variable clinical course, and thus novel prognostic biomarkers are needed. The heme biosynthesis cycle constitutes a fundamental metabolic pathway and might play a crucial role in glioma biology. The aim of this study was thus to investigate the role of the heme biosynthesis mRNA expression signature on prognosis in a large glioma patient cohort. Glioma patients with available sequencing data on heme biosynthesis expression were retrieved from The Cancer Genome Atlas (TCGA). In each patient, the heme biosynthesis mRNA expression signature was calculated and categorized into low, medium, and high expression subgroups. Differences in progression-free and overall survival between these subgroups were investigated including a multivariate analysis correcting for WHO grade, tumor subtype, and patient age and sex. In a total of 693 patients, progression-free and overall survival showed a strictly monotonical decrease with increasing mRNA expression signature subgroups. In detail, median overall survival was 134.2 months in the low, 79.9 months in the intermediate, and 16.5 months in the high mRNA expression signature subgroups, respectively. The impact of mRNA expression signature on progression-free and overall survival was independent of the other analyzed prognostic factors. Our data indicate that the heme biosynthesis mRNA expression signature might serve as an additional novel prognostic marker in patients with diffusely infiltrating gliomas to optimize postoperative management. MDPI 2021-02-07 /pmc/articles/PMC7916021/ /pubmed/33562253 http://dx.doi.org/10.3390/cancers13040662 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mischkulnig, Mario
Kiesel, Barbara
Lötsch, Daniela
Roetzer, Thomas
Borkovec, Martin
Wadiura, Lisa I.
Roessler, Karl
Hervey-Jumper, Shawn
Penninger, Josef M.
Berger, Mitchel S.
Widhalm, Georg
Erhart, Friedrich
Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
title Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
title_full Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
title_fullStr Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
title_full_unstemmed Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
title_short Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
title_sort heme biosynthesis mrna expression signature: towards a novel prognostic biomarker in patients with diffusely infiltrating gliomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916021/
https://www.ncbi.nlm.nih.gov/pubmed/33562253
http://dx.doi.org/10.3390/cancers13040662
work_keys_str_mv AT mischkulnigmario hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT kieselbarbara hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT lotschdaniela hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT roetzerthomas hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT borkovecmartin hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT wadiuralisai hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT roesslerkarl hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT herveyjumpershawn hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT penningerjosefm hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT bergermitchels hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT widhalmgeorg hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas
AT erhartfriedrich hemebiosynthesismrnaexpressionsignaturetowardsanovelprognosticbiomarkerinpatientswithdiffuselyinfiltratinggliomas